PCM
SYRS

Portolan Capital Management’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Portolan Capital Management’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-38,192
Closed -$4.14M – 183
2020
Q4 		$4.14M Sell
38,192
-6,894
-15% -$629K 0.38% 98
2020
Q3 		$3.99M Sell
45,086
-4,781
-10% -$543K 0.45% 86
2020
Q2 		$5.32M Sell
49,867
-1,390
-3% -$125K 0.61% 68
2020
Q1 		$3.04M Buy
51,257
+18,572
+57% +$1.26M 0.46% 73
2019
Q4 		$2.26M Buy
+32,685
New +$1.98M 0.23% 84

Other funds holding SYRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ABG
Ally Bridge Group New York $113M AUM 245.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Portolan Capital Management's SYRS Position: Q1 2021 in Review

Portolan Capital Management sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2021, closing a stake of 38,192 shares — an estimated $4.14M sold.

Portolan Capital Management first reported a position in SYRS in Q4 2019 and held it in 5 quarters. The position peaked at $5.32M in Q2 2020. 106 funds tracked by Wall St. Rank hold SYRS as of Q1 2021.

  • Portolan Capital Management reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Portolan Capital Management sold 38,192 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2021, an estimated $4.14M.
  • Portolan Capital Management first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2019 and held it in 5 quarters.
  • Portolan Capital Management's Syros Pharmaceuticals, Inc. Common Stock position peaked at $5.32M in Q2 2020.
  • 106 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2021.

Based on Portolan Capital Management's 13F filing for Q1 2021, filed 17 May 2021.